Emijoy DS Tablet
Chlordiazepoxide
25 mg + 10 Mg
Beximco Pharmaceuticals Ltd.
| Pack size | 30's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 12.00 AED |
Indications
Emijoy DS Tablet is used for:
Anxiety, Insomnia, Muscle spasms, Acute symptoms of alcohol withdrawal
Adult Dose
Oral
Insomnia
Adult: 10-30 mg before bedtime.
Muscle spasms
Adult: 10-30 mg daily in divided doses.
Anxiety
Adult: 30 mg daily in divided doses, up to 100 mg daily in severe conditions.
Acute symptoms of alcohol withdrawal
Adult: 25-100 mg daily repeated as necessary.
Max dose: 300 mg daily.
Child Dose
Anxiety
<6 years: Safety and efficacy not established
>6 years: 0.5 mg/kg/day divided PO q6-8hr,
OR 5 mg PO q6-12hr; may increase dose to 10 mg PO q8-12hr
Renal Dose
Renal impairment
CrCl <10 mL/min: 50% of recommended dose
CrCl >10 mL/min: Dose adjustment not necessary (monitor)
Administration
May be taken with or without food.
Contra Indications
Acute pulmonary insufficiency, resp depression, patients with marked neuromuscular resp weakness; hypersensitivity to benzodiazepines; chronic psychosis; porphyria; pregnancy and lactation.
Precautions
Concomitant use of benzodiazepines and opioids may result in profound respiratory depression, coma, and death; administer concomitantly when there are no alternative options; limit dosages and durations to minimum required; monitor for signs and symptoms of respiratory depression and sedation
Addiction, abuse, and misuse
On September 2020, FDA addressed serious risks of benzodiazepine addiction, abuse, and misuse, which can lead to overdose and death
Physical dependence can occur when taken steadily for several days to weeks, even as prescribed
Stopping abruptly or reducing dosage too quickly can result in withdrawal reactions, including seizures, which can be life-threatening
Assess each patient’s risk prior to prescribing and monitor regularly for the development of these behaviors or conditions
Patient should be observed for up to 3 hours following administration
Anterograde amnesia associated with treatment
Use caution in renal and hepatic impairment
Use caution in respiratory disease (COPD), sleep apnea, porphyria, open-angle glaucoma (questionable), depression, suicidal ideation, impaired gag reflex
May impair ability to perform hazardous tasks
Paradoxical reactions, including hyperactive or aggressive behavior, reported
Use caution in patients with depression, especially if suicidal risk present
Ataxia and oversadation may occur in the elderly and debilitated patients; there also increased risk of falls
Use caution in patients with history of drug abuse or acute alcoholism; tolerance, psychological and physical dependence may occur with prolonged use
Pregnancy-Lactation
Pregnancy category: D
Lactation: Enters breast milk/not recommended
Interactions
Cimetidine increases serum conc of chlordiazepoxide.
Potentiates the action of major neuroleptics.
The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines
and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation.
Potentially Fatal: Alcohol potentiates CNS-depressant effect of chlordiazepoxide.
Contraindicated (0)
Serious (33)
apalutamide
benzhydrocodone/acetaminophen
buprenorphine subdermal implant
buprenorphine transdermal
buprenorphine, long-acting injection
calcium/magnesium/potassium/sodium oxybates
conivaptan
dacomitinib
enzalutamide
fentanyl
fentanyl intranasal
fentanyl iontophoretic transdermal system
fentanyl transdermal
fentanyl transmucosal
fexinidazole
hydrocodone
idelalisib
ivosidenib
lonafarnib
methohexital
metoclopramide intranasal
nefazodone
oliceridine
olopatadine intranasal
opicapone
remifentanil
selinexor
sodium oxybate
sufentanil SL
tolcapone
tucatinib
valerian
zuranolone
Adverse Effects
Side effects of Chlordiazepoxide :
>10%
Ataxia,Drowsiness,Memory impairment,Sedation,Muscle weakness,Rash,Decreased libido,Menstrual disorders,Xerostomia,Salivation decreased,Increased/decreased appetite,Weight gain/loss,Micturition difficulties
1-10%
Confusion,Dizziness,Disinhibition,Akathisia,Dermatitis,Hypotension,Salivation increased,Sexual dysfunction,Incontinence,Rigidity,Tremor,Muscle cramps,Tinnitus,Nasal congestion
Mechanism of Action
Chlordiazepoxide enhances activity of the inhibitory transmitter GABA in different parts of CNS by increasing neuronal-membrane permeability to chloride ions resulting to hyperpolarisation and stabilisation. It has some muscle relaxant and anticonvulsant activity.
Note
Emijoy DS 25 mg + 10 Mg Tablet manufactured by Beximco Pharmaceuticals Ltd.. Its generic name is Chlordiazepoxide. Emijoy DS is availble in Bangladesh.
Farmaco BD drug index information on Emijoy DS Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.